| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 454 | 2020 |
| Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas M Verreault, C Schmitt, L Goldwirt, K Pelton, S Haidar, C Levasseur, ... Clinical Cancer Research 22 (5), 1185-1196, 2016 | 108 | 2016 |
| Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK) LA Edwards, J Woo, LA Huxham, M Verreault, WH Dragowska, G Chiu, ... Molecular cancer therapeutics 7 (1), 59-70, 2008 | 105 | 2008 |
| Blood-brain barrier, cytotoxic chemotherapies and glioblastoma A Dréan, L Goldwirt, M Verreault, M Canney, C Schmitt, J Guehennec, ... Expert review of neurotherapeutics 16 (11), 1285-1300, 2016 | 101 | 2016 |
| Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice C Lee, A Fotovati, J Triscott, J Chen, C Venugopal, A Singhal, C Dunham, ... Stem cells 30 (6), 1064-1075, 2012 | 89 | 2012 |
| Challenges in glioblastoma research: focus on the tumor microenvironment A Bikfalvi, CA da Costa, T Avril, JV Barnier, L Bauchet, L Brisson, ... Trends in cancer 9 (1), 9-27, 2023 | 86 | 2023 |
| Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma A Dréan, N Lemaire, G Bouchoux, L Goldwirt, M Canney, L Goli, A Bouzidi, ... Journal of neuro-oncology 144, 33-41, 2019 | 72 | 2019 |
| Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells LA Edwards, M Verreault, B Thiessen, WH Dragowska, Y Hu, JHF Yeung, ... Molecular cancer therapeutics 5 (3), 645-654, 2006 | 71 | 2006 |
| A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma EA El-Habr, LG Dubois, F Burel-Vandenbos, A Bogeas, J Lipecka, ... Acta neuropathologica 133, 645-660, 2017 | 68 | 2017 |
| Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin … M Verreault, D Strutt, D Masin, M Anantha, A Yung, P Kozlowski, ... BMC cancer 11, 1-18, 2011 | 68 | 2011 |
| SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia LH Geraldo, Y Xu, L Jacob, L Pibouin-Fragner, R Rao, N Maissa, ... The Journal of clinical investigation 131 (16), 2021 | 54 | 2021 |
| ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma A Dréan, S Rosenberg, FX Lejeune, L Goli, AA Nadaradjane, ... Journal of neuro-oncology 138, 479-486, 2018 | 54 | 2018 |
| A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas S Rosenberg, I Simeonova, F Bielle, M Verreault, B Bance, I Le Roux, ... Nature Communications 9 (1), 2371, 2018 | 53 | 2018 |
| Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors S Rosenberg, M Verreault, C Schmitt, J Guegan, J Guehennec, ... Neuro-oncology 19 (2), 219-228, 2017 | 52 | 2017 |
| Etoposide improves survival in high-grade glioma: a meta-analysis A Leonard, JE Wolff Anticancer research 33 (8), 3307-3315, 2013 | 43 | 2013 |
| New hints towards a precision medicine strategy for IDH wild-type glioblastoma K White, K Connor, J Clerkin, BM Murphy, M Salvucci, AC O'Farrell, ... Annals of Oncology 31 (12), 1679-1692, 2020 | 42 | 2020 |
| Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model M Verreault, SA Weppler, A Stegeman, C Warburton, D Strutt, D Masin, ... PloS one 8 (3), e59597, 2013 | 35 | 2013 |
| Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy K White, K Connor, M Meylan, A Bougoüin, M Salvucci, F Bielle, ... Annals of Oncology 34 (3), 300-314, 2023 | 34 | 2023 |
| Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems M Verreault, MS Webb, EC Ramsay, MB Bally Current gene therapy 6 (4), 505-533, 2006 | 34 | 2006 |
| Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model M Verreault, D Strutt, D Masin, M Anantha, D Waterhouse, DT Yapp, ... Journal of controlled release 158 (1), 34-43, 2012 | 26 | 2012 |
